New biomedical approaches for sexually transmitted infection prevention: Vaccines and microbicides

Adolescent Medicine Clinics

Volumn 15, Issue 2, 2004, Pages 393-407

  Rupp, Richard ^a   Stanberry, Lawrence R ^a   Rosenthal, Susan L ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIBODY; ANTIGEN; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BENZALKONIUM CHLORIDE; BIOLOGICAL PRODUCT; BUFFER; CAPSID PROTEIN; CELLULOSE SULFATE; CHIRON VACCINE; CHLAMYDIA VACCINE; DEXTRIN; DEXTRIN 2 SULFATE; DNA VACCINE; GONORRHEA VACCINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN E7 VACCINE; HEPATITIS B VACCINE; HERPES VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; N 9; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NONOXINOL 9; PHOSPHORYL LIPID A; RECOMBINANT VACCINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ADOLESCENCE; ANTIBODY RESPONSE; BEHAVIOR; BIOMEDICINE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE GENITAL SYSTEM; FINANCIAL MANAGEMENT; GENE MAPPING; HEALTH CARE PERSONNEL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HOST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MALE GENITAL SYSTEM; MARKETING; NEISSERIA GONORRHOEAE; NONHUMAN; PARENT; PLASMID; PROPHYLAXIS; PROTECTION; PROTEIN CONFORMATION; REVIEW; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; T LYMPHOCYTE; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS VECTOR; WART VIRUS;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ANTI-INFECTIVE AGENTS, LOCAL; HUMANS; SEXUALLY TRANSMITTED DISEASES; VACCINES;

EID: 3142634642     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2004.02.010     Document Type: Review

References (78)

1. Institute of Medicine The hidden epidemic: confronting sexually transmitted diseases. Eng T.R., Butler W.T. 1997;National Academy Press, Washington (DC)
2. UNAIDS Epidemiology. Available at: http://www.unaids.org/en/resources/ epidemiology.asp. Accessed September 27, 2003
3. Cates W. Estimates of incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis. 26:1999;S2-S7
4. Brunham R.C., McClarity G. Chlamydia. Stanberry L.R., Bernstein D.I. Sexually transmitted disease: vaccines, prevention and control. 2000;339-368 Academic Press, San Diego (CA)
5. Igietseme J.U., Eko F.O., Black C.M. Contemporary approaches designing and evaluating vaccines against chlamydia [serial online]. Available at: http://www.future-drugs.com. Accessed September 24, 2003 Expert Rev Vaccines. 2(1):2003;129-146
6. World Health Organization Initiative for vaccine research. Available at: http://www.who.int/vaccine_research/documents/new_vaccines/en/index3.html. Accessed April 22, 2004
7. Brunham R.C., Zhang D.J., Yang X., McClarty G.M. The potential for vaccine development against chlamydial infection and disease. J Infect Dis. 181:2000;s538-s543
8. Zenilman J.M., Deal C.D. Gonorrhea: epidemiology, control and prevention. Stanberry L.R., Bernstein D.I. Sexually transmitted disease: vaccines, prevention and control. 2000;369-386 Academic Press, San Diego (CA)
9. Gulati S., Ngampasutadol J., Yamasaki R., McQuillen D.P., Rice P.A. Strategies for mimicking neisserial saccharide epitopes as vaccines. Int Rev Immunol. 20:2001;229-250
10. Vandepapileire P. Therapeutic vaccines for the control of human papillomavirus chronic infections. Stanberry L.R., Bernstein D.I. Sexually transmitted disease: vaccines, prevention and control. 2000;273-294 Academic Press, San Diego (CA)
11. Lowy D.R., Kirnbauer R., Schiller J.T. Genital human papillomavirus infection. Proc Natl Acad Sci USA. 91:1994;2436-2440
12. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 93(4):2001;284-292
13. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune response to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis. 188:2003;327-338
14. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 347:2002;1645-1651
15. Dubin G. Development of an adjuvanted human papillomavirus type 16/18 L1 virus like particle [abstract SS 205]. Eurogin 2003 5th International Multidisciplinary Congress, Preventing and Controlling Cervical Cancer in the New Millennium. 2003;207 Eurogin, Paris
16. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 95:2003;1128-1137
17. Lacey C.J., Thompson H.S., Monteiro E.F., O'Neill T., Davies M.L., Holding F.P., et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis. 179:1999;612-618
18. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527
19. Goldstone S.E., Palefsky J.M., Winnett M.T., Neefe J.R. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum. 45(4):2002;502-507
20. Guttman C. Novel vaccine promising in the treatment of genital warts [serial online]. Dermatology Times. Feb 1, 2002;. Available at: http://www.dermatologytimes.com/dermatologytimes/article/articleDetail.jsp?id= 10134. Accessed on March 29, 2004
21. rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003;295 Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington (DC)
22. Burke R.L. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol. 179:1992;137-158
23. Bernstein D.I., Stanberry L.R. Herpes simplex virus vaccines. Vaccine. 17:1999;1681-1689
24. Krause P.R., Straus S.E. Herpesvirus vaccines. Development, controversies, and applications. Infect Dis Clin North Am. 13:1999;61-81
25. Stanberry L.R., Cunningham A.L., Mindel A., Scott L.L., Spruance S.L., Aoki F.Y., et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis. 30:2000;549-566
26. Koelle D.M., Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 16:2003;96-113
27. Vestergaard B.F. Herpes simplex virus antigens and antibodies: a survey of studies based on quantitative immunoelectrophoresis. Rev Infect Dis. 2:1980;899-913
28. Berman P.W., Gregory T., Crase D., Lasky L.A. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science. 227:1985;1490-1492
29. Dix R.D., Mills J. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD. J Med Virol. 17:1985;9-18
30. Kino Y., Eto T., Nishiyama K., Ohtomo N., Mori R. Immunogenicity of purified glycoprotein gB of herpes simplex virus. Arch Virol. 89(1-4):1986;69-80
31. Stanberry L.R., Bernstein D.I., Burke R.L., Pachl C., Myers M.G. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis. 155:1987;914-920
32. Burke R.L. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev Infect Dis. 13(Suppl 11):1991;S906-S911
33. Bourne N., Bravo F.J., Francotte M., Bernstein D.I., Myers M.G., Slaoui M., et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis. 187:2003;542-549
34. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2. Ann Intern Med. 122:1995;889-898
35. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 282:1999;331-340
36. Leroux-Roels G., Moreau E., Desombere I., et al. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL [abstract]. Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4-7, 1994:1994;205 American Society for Microbiology, Washington (DC)
37. Francotte M., Pala P., Van Opstal O., et al. Comparative safety and immunogenicity of two adjuvant formulations of an HSV-2 glycoprotein D based subunit vaccine in man [abstract]. Abstracts of the 18th International Herpesvirus Workshop, Pittsburgh, July 25-30, 1993:1993;C38 University of Pittsburgh, Pittsburgh
38. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 347:2002;1652-1661
39. Fleming D.T., McQuillan G.M., Johnson R.E., et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 337:1997;1105-1111
40. Garnett G.P., Dubin G., Slaoui M., Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Trans Inf. 80:2004;24-29
41. Rosenthal S.L., Stanberry L.R., Biro F.M., et al. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis. 24:1997;135-139
42. Stanberry L.R., Rosenthal S.L. Epidemiology of herpes simplex virus infections in adolescents. Herpes. 6:1999;12-15
43. Sucato G., Celum C., Dithmer D., Ashley R., Wald A. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. Pediatr Infect Dis J. 20:2001;422-426
44. Smith J.S., Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 186(Suppl 1):2002;S3-S28
45. Siegel R.M., Baker R.C., Kotagal U.R., Balistreri W.F. Hepatitis B vaccine use in Cincinnati: a community's response to the AAP recommendation of universal hepatitis B immunization. J Natl Med Assoc. 86:1994;444-448
46. Britto M.T., Atherton H.D., DeWitt T.G. Immunizing adolescents in private practice: lessons learned from hepatitis B. Prev Med Managed Care. 2:2001;127-134
47. Cassidy W. School-based adolescent hepatitis B immunization programs in the United States: strategies and successes. Pediatr Infect Dis J. 17:1998;S43-S46
48. Guajardo A.D., Middleman A.B., Sansaricq K.M. School nurses identify barriers and solutions to implementing a school-based hepatitis B immunization program. J Sch Health. 72(3):2002;128-130
49. Middleman A.B., Guajardo A.D., Sunwoo E., Sansaricq K.M. Parent knowledge and attitudes about school-based hepatitis B immunization programs. J Sch Health. 72:2002;348-351
50. Mays R.M., Sturm L.A., Zimet G.D. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 58(7):2004;1405-1413
51. Lazcano-Ponce E., Rivera L., Arillo-Santillan E., Salmeron J., Hernandez-Avila M., Munoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 32:2001;243-247
52. Kahn J.A., Rosenthal S.L., Hamann T., Bernstein D.I. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS. 14:2003;300-306
53. Boehner C.W., Howe S.R., Bernstein D.I., Rosenthal S.L. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 30:2003;774-778
54. Hoover D.R., Carfioli B., Moench E.A. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int. 21:2000;375-391
55. Rosenthal S.L., Lewis L.M., Succop P.A., Bernstein D.I., Stanberry L.R. College students' attitudes regarding vaccination to prevent genital herpes. Sex Trans Dis. 26:1999;438-443
56. Zimet G.D., Mays R.M., Winston Y., Kee R., Dickes J., Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 9:2000;47-50
57. Webb P.M., Zimet G.D., Mays R., Fortenberry J.D. HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents. J Adolesc Health. 25:1999;320-322
58. Zimet G.D., Fortenberry J.D., Fife K.H., Tyring S.K., Herne K., Douglas J.M. Acceptability of genital herpes immunization. The role of health beliefs and health behaviors. Sex Transm Dis. 24:1997;555-560
59. Rosenthal S.L., Cohen S.S., Stanberry L.R. Topical microbicides: current status and research considerations for adolescent girls. Sex Transm Dis. 25:1998;368-377
60. Coggins C. Avoiding HIV transmission: women need more options. Sex Transm Infect. 75:1999;374-375
61. Harrison P.F. The microbicide research and development "pipeline": a status report. Presented at the Microbicides 2002 Meeting. Antwerp, Belgium, May 13, 2002
62. Rosenberg Z.F. Topical microbicide research and development at NIAID. Presented at the 1999 National HIV Prevention Conference. Atlanta, GA, August 29-September 1, 1999
63. Bowcut J.C. Clinical trials information center. 2003;Alliance for Microbicide Development, Silver Spring (MD)
64. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360:2002;971-977
65. WHO/CONRAD Technical Consultation on Nonoxynol-9. Conrad. 2001;World Health Organization, Geneva (Switzerland)
66. Mauck C., Rosenberg Z., Van Damme L. Recommendations for the clinical development of topical microbicides: an update. AIDS. 15:2001;857-868
67. Hammett T.M., Mason T.H., Joanis C.L., et al. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities. Sex Transm Dis. 27:2000;119-126
68. Bentley M.E., Morrow K.M., Fullem A., Chesney M.A., Horton S.D., Rosenberg Z., et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect. 32(4):2000;184-188
69. Hardy E., de Padua K.S., Osis M.J.D., Jimenez A.L., Zaneveld L.J. Women's preferences for vaginal antimicrobial contraceptives IV attributes of a formulation that would protect from STD / AIDS. Contraception. 58:1998;251-255
70. Darroch J.E., Frost J.J. Women's interest in vaginal microbicides. Fam Plann Perspect. 31:1999;16-23
71. Hillier L., Harrison L., Warr D. "When you carry condoms all the boys think you want it:" negotiating competing discourses about safe sex. J Adolesc. 21(1):1998;15-29
72. Short M.B., Mills L., Majkowski J.M., Stanberry L.R., Rosenthal S.L. Topical microbicide use by adolescent girls: concerns about timing, efficacy, and safety. Sex Transm Dis. 30:2003;854-858
73. Rosenthal S.L., Cohen S.S., Gevelber M., Stanberry L.R. Young men's views about topical microbicides. Int J STD AIDS. 12:2001;279-280
74. Rosenthal S.L., Cohen S.S. Primary prevention of sexually transmitted disease: self-efficacy in the context of sexual coercion. Adolesc Pediatric Gynecol. 7:1994;63-68
75. Rosenthal S.L., Cohen S.S., DeVellis R.F., Biro F.M., Lewis L.M., Succop P.A., et al. Locus of control for general health and STD acquisition among adolescent girls. Sex Transm Dis. 26:1999;472-475
76. Malow R.M., Ziskind D., Jones D.L. Use of female controlled microbicidal products for HIV risk reduction. AIDS Care. 12:2000;581-588
77. Jones D.L., Weiss S.M., Malow R., Ishii M., Devieux J., Stanley H., et al. A brief sexual barrier intervention for women living with AIDS: acceptability, use, and ethnicity. J Urban Health. 78:2001;593-604
78. Rosenthal S.L., Biro F.M., Kollar L.M., Hillard P.J., Rauh J.L. Experience with side effects and health risks associated with Norplant implant use in adolescents. Contraception. 52:1995;283-285